Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
- Conditions
- Gout
- Interventions
- Other: PlaceboBiological: Rilonacept
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1315
- Registration Number
- NCT00856206
PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
- Conditions
- Intercritical Gout
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 241
- Registration Number
- NCT00829829
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
- Conditions
- Advanced CarcinomaNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00794417
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States
🇺🇸Kentucky Cancer Clinic, Hazard, Kentucky, United States
DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
- Conditions
- Diabetic Macular Edema
- Interventions
- Procedure: Laser Photocoagulation
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 221
- Registration Number
- NCT00789477
Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT00609544
Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
- Conditions
- Gout
- Interventions
- Biological: RilonaceptOther: Placebo (for Rilonacept)
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 83
- Registration Number
- NCT00610363
Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
- Conditions
- Macular Degeneration
- Interventions
- Drug: VEGF Trap Eye
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 157
- Registration Number
- NCT00527423
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
- Conditions
- Macular Degeneration
- Interventions
- Biological: ranibizumabBiological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2012-12-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1217
- Registration Number
- NCT00509795
Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Biological: VEGF Trap
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00383370
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
- Conditions
- Macular Degeneration
- Interventions
- Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2012-03-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 159
- Registration Number
- NCT00320788
- Locations
- 🇺🇸
Southeast Retina Center, Augusta, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Charlotte Eye, Ear, Nose & Throat Asssociates, Charlotte, North Carolina, United States